Efficacy of octreotide acetate in treatment of severe postgastrectomy dumping syndrome.

Geer RJ, Richards WO, O'Dorisio TM, Woltering EO, Williams S, Rice D, Abumrad NN

Annals of surgery1 Dec 1990Cited by 64 (Europe PMC)

PMID2256759DOI10.1097/00000658-199012000-00005PepBankPUB-02256759

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

13 results from studies that gave the peptide. 13 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with severe dumping, octreotide prevented vasomotor symptoms versus placebo.
In plain wordsIn patients with severe dumping, octreotide prevented vasomotor symptoms versus placebo.
Peptide
Octreotide
Outcome
DecreaseVasomotor symptoms
Study
n = 10
Comparator
Placebo
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
100 micrograms · subcutaneousAs given in this study (human).
Source sentences
Summary
Treatment with octreotide acetate prevented the development of both vasomotor and gastrointestinal symptoms and completely ablated all of the above responses in plasma peptides.
2 context sentences(design, population, supporting numbers)
Summary · context
In the acute phase, 10 patients with severe dumping were studied over 2 consecutive days before and for 3 hours after the ingestion of a 'dumping breakfast' in a randomized double-blind fashion.
Summary · context
On one day octreotide (100 micrograms) was given subcutaneously 30 minutes before the test meal and on the other day an equal volume of vehicle was injected.
Report a problemFND-0225675901
02HumanRandomized controlled trialEfficacy outcome
In patients with severe dumping, octreotide prevented gastrointestinal symptoms versus placebo.
In plain wordsIn patients with severe dumping, octreotide prevented gut symptoms versus placebo.
Peptide
Octreotide
Outcome
DecreaseGastrointestinal symptoms
Study
n = 10
Comparator
Placebo
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
100 micrograms · subcutaneousAs given in this study (human).
Source sentences
Summary
Treatment with octreotide acetate prevented the development of both vasomotor and gastrointestinal symptoms and completely ablated all of the above responses in plasma peptides.
2 context sentences(design, population, supporting numbers)
Summary · context
In the acute phase, 10 patients with severe dumping were studied over 2 consecutive days before and for 3 hours after the ingestion of a 'dumping breakfast' in a randomized double-blind fashion.
Summary · context
On one day octreotide (100 micrograms) was given subcutaneously 30 minutes before the test meal and on the other day an equal volume of vehicle was injected.
Report a problemFND-0225675902
03HumanRandomized controlled trialEfficacy outcome
In patients with severe dumping, octreotide completely ablated the reported plasma peptide responses versus placebo.
In plain wordsIn patients with severe dumping, octreotide blocked the reported blood peptide responses versus placebo.
Peptide
Octreotide
Outcome
DecreasePostprandial plasma peptide responses
Study
n = 10
Comparator
Placebo
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
100 micrograms · subcutaneousAs given in this study (human).
Source sentences
Summary
Treatment with octreotide acetate prevented the development of both vasomotor and gastrointestinal symptoms and completely ablated all of the above responses in plasma peptides.
3 context sentences(design, population, supporting numbers)
Summary · context
During placebo treatment the test meal resulted in an immediate increase (p less than 0.01) in the pulse rate and in plasma levels of glucose, glucagon, pancreatic polypeptide, neurotensin, and insulin.
Summary · context
In the acute phase, 10 patients with severe dumping were studied over 2 consecutive days before and for 3 hours after the ingestion of a 'dumping breakfast' in a randomized double-blind fashion.
Summary · context
On one day octreotide (100 micrograms) was given subcutaneously 30 minutes before the test meal and on the other day an equal volume of vehicle was injected.
Report a problemFND-0225675903
04HumanRandomized controlled trialEfficacy outcome
In patients with severe dumping, octreotide completely ablated diarrhea (p less than 0.001).
In plain wordsIn patients with severe dumping, octreotide prevented diarrhea versus placebo.
Peptide
Octreotide
Outcome
DecreaseDiarrhea
Study
n = 10
Comparator
Placebo
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
100 micrograms · subcutaneousAs given in this study (human).
Measurements
p-value
< 0.001 p
octreotide versus placebo, diarrhea
Source sentences
Summary
These changes were associated with complete ablation of diarrhea (p less than 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
In the acute phase, 10 patients with severe dumping were studied over 2 consecutive days before and for 3 hours after the ingestion of a 'dumping breakfast' in a randomized double-blind fashion.
Summary · context
On one day octreotide (100 micrograms) was given subcutaneously 30 minutes before the test meal and on the other day an equal volume of vehicle was injected.
Report a problemFND-0225675904
05HumanRandomized controlled trialEfficacy outcome
In patients with severe dumping, octreotide completely suppressed the meal-induced plasma insulin rise.
In plain wordsIn patients with severe dumping, octreotide blocked the insulin rise after a meal versus placebo.
Peptide
Octreotide
Outcome
DecreasePostprandial insulin response
Study
n = 10
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
100 micrograms · subcutaneousAs given in this study (human).
Source sentences
Summary
Pretreatment with octreotide acetate completely suppressed the rise in plasma insulin response to the meal and this ablated the late hypoglycemia of dumping.
2 context sentences(design, population, supporting numbers)
Summary · context
In the acute phase, 10 patients with severe dumping were studied over 2 consecutive days before and for 3 hours after the ingestion of a 'dumping breakfast' in a randomized double-blind fashion.
Summary · context
On one day octreotide (100 micrograms) was given subcutaneously 30 minutes before the test meal and on the other day an equal volume of vehicle was injected.
Report a problemFND-0225675905
06HumanRandomized controlled trialEfficacy outcome
In patients with severe dumping, octreotide ablated late hypoglycemia.
In plain wordsIn patients with severe dumping, octreotide prevented late low blood sugar versus placebo.
Peptide
Octreotide
Outcome
DecreaseLate hypoglycemia
Study
n = 10
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
100 micrograms · subcutaneousAs given in this study (human).
Source sentences
Summary
Pretreatment with octreotide acetate completely suppressed the rise in plasma insulin response to the meal and this ablated the late hypoglycemia of dumping.
2 context sentences(design, population, supporting numbers)
Summary · context
In the acute phase, 10 patients with severe dumping were studied over 2 consecutive days before and for 3 hours after the ingestion of a 'dumping breakfast' in a randomized double-blind fashion.
Summary · context
On one day octreotide (100 micrograms) was given subcutaneously 30 minutes before the test meal and on the other day an equal volume of vehicle was injected.
Report a problemFND-0225675906
07HumanRandomized controlled trialEfficacy outcome
In patients with severe dumping, octreotide delayed gastric emptying and transit time: 578 +/- 244 minutes versus 76 +/- 23 minutes with placebo and 125 +/- 36 minutes in controls (p less than 0.05).
In plain wordsIn patients with severe dumping, octreotide slowed stomach emptying and gut transit compared with placebo.
Peptide
Octreotide
Outcome
IncreaseGastric emptying and transit time
Study
n = 10
Comparator
Placebo
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
100 micrograms · subcutaneousAs given in this study (human).
Measurements
Gastric emptying and transit time
578 minutes
octreotide, severe dumping, SD 244
Gastric emptying and transit time
76 minutes
placebo, severe dumping, SD 23
Gastric emptying and transit time
125 minutes
controls without dumping, SD 36
p-value
< 0.05 p
reported comparison
Source sentences
Summary
Treatment with octreotide acetate resulted in delayed gastric emptying and transit time (578 +/- 244 minutes) versus 76 +/- 23 minutes with placebo and 125 +/- 36 minutes in controls (p less than 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
In the acute phase, 10 patients with severe dumping were studied over 2 consecutive days before and for 3 hours after the ingestion of a 'dumping breakfast' in a randomized double-blind fashion.
Summary · context
On one day octreotide (100 micrograms) was given subcutaneously 30 minutes before the test meal and on the other day an equal volume of vehicle was injected.
Report a problemFND-0225675907
08HumanRandomized controlled trialEfficacy outcome
In patients with severe dumping, octreotide increased transit time to 578 +/- 244 minutes versus 76 +/- 23 with placebo (p less than 0.05).
In plain wordsIn patients with severe dumping, octreotide increased gut transit time versus placebo.
Peptide
Octreotide
Outcome
IncreaseTransit time versus placebo
Study
n = 10
Comparator
Placebo
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
100 micrograms · subcutaneousAs given in this study (human).
Measurements
Gastric emptying and transit time
578 minutes
octreotide 100 micrograms sc, dumping patients; +/- 244
Gastric emptying and transit time
76 minutes
placebo (vehicle), dumping patients; +/- 23
Source sentences
Summary
Treatment with octreotide acetate resulted in delayed gastric emptying and transit time (578 +/- 244 minutes) versus 76 +/- 23 minutes with placebo and 125 +/- 36 minutes in controls (p less than 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
In the acute phase, 10 patients with severe dumping were studied over 2 consecutive days before and for 3 hours after the ingestion of a 'dumping breakfast' in a randomized double-blind fashion.
Summary · context
On one day octreotide (100 micrograms) was given subcutaneously 30 minutes before the test meal and on the other day an equal volume of vehicle was injected.
Report a problemFND-0225675908
09HumanNon-randomized trialSafety outcome
In patients with severe dumping, chronic daily octreotide produced minimal side effects.
In plain wordsIn patients with severe dumping, daily octreotide produced minimal side effects.
Peptide
Octreotide
Outcome
Direction not reportedChronic side effects
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Source sentences
Summary
Chronic daily treatment with octreotide acetate resulted in minimal side effects.
Report a problemFND-0225675910
10HumanNon-randomized trialEfficacy outcome
In patients with severe dumping, fasting plasma glucose remained stable during chronic daily octreotide treatment.
In plain wordsIn patients with severe dumping, fasting blood sugar stayed stable during daily octreotide treatment.
Peptide
Octreotide
Outcome
No significant changeFasting plasma glucose
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
These patients demonstrated a stable fasting plasma glucose, normal liver function tests, and an average weight gain of 11% during a 12-month period.
1 context sentence(design, population, supporting numbers)
Summary · context
Chronic daily treatment with octreotide acetate resulted in minimal side effects.
Report a problemFND-0225675911
11HumanNon-randomized trialEfficacy outcome
In patients with severe dumping, liver function tests were normal during chronic daily octreotide treatment.
In plain wordsIn patients with severe dumping, liver tests were normal during daily octreotide treatment.
Peptide
Octreotide
Outcome
Not applicableLiver function tests
Study
n: not reported in source
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
These patients demonstrated a stable fasting plasma glucose, normal liver function tests, and an average weight gain of 11% during a 12-month period.
1 context sentence(design, population, supporting numbers)
Summary · context
Chronic daily treatment with octreotide acetate resulted in minimal side effects.
Report a problemFND-0225675912
12HumanNon-randomized trialEfficacy outcome
In patients with severe dumping, chronic daily octreotide treatment accompanied an average weight gain of 11% during 12 months.
In plain wordsIn patients with severe dumping, average weight increased 11% during 12 months of daily octreotide treatment.
Peptide
Octreotide
Outcome
IncreaseWeight gain
Study
n: not reported in source
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
Average weight gain
11%
chronic daily octreotide, 12-month period
Source sentences
Summary
These patients demonstrated a stable fasting plasma glucose, normal liver function tests, and an average weight gain of 11% during a 12-month period.
1 context sentence(design, population, supporting numbers)
Summary · context
Chronic daily treatment with octreotide acetate resulted in minimal side effects.
Report a problemFND-0225675913
13HumanNon-randomized trialEfficacy outcome
Most patients with severe dumping could resume employment during chronic octreotide treatment.
In plain wordsMost patients with severe dumping could return to work during daily octreotide treatment.
Peptide
Octreotide
Outcome
Not applicableReturn to employment
Study
n: not reported in source
Outcome group
Exercise and physical function · Whole body
Studied dose
Dose not stated
Source sentences
Summary
In addition most patients were able to resume employment.
1 context sentence(design, population, supporting numbers)
Summary · context
Chronic daily treatment with octreotide acetate resulted in minimal side effects.
Report a problemFND-0225675914

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.